Oxazaphosphorine alkylators & the proximal tubule
Ifosfamide Fanconi syndrome
Mesna guards the bladder, but nothing guards the proximal tubule — ifosfamide's chloroacetaldehyde metabolite is made inside the tubular cell itself, draining its energy and its reabsorptive machinery until phosphate, glucose, bicarbonate, and amino acids leak into the urine.
- 4%
- Fanconi-like syndromeIncidence of overt Fanconi-like syndrome with high-dose ifosfamide in a prospective children/young-adult cohort — while acute subclinical tubular changes were seen in every patient
- 100 g/m²
- cumulative-dose ceilingIn Skinner's landmark cohort total ifosfamide dose was the only independent risk factor; cumulative doses ≥100 g/m² should be avoided in children
- 45%
- reduced GFRGlomerular filtration rate below normal (61–85 mL/min/1.73m²) in 10 of 22 evaluable children after ifosfamide
- 70×
- β2-microglobulinuriaMedian rise in urinary β2-microglobulin after a single 5-day ifosfamide cycle — the low-molecular-weight proteinuria that flags proximal tubular injury and predicted chronic damage
- despite mesna
- no tubular protectionTubular enzymuria and proteinuria rose in every patient given ifosfamide with mesna — mesna prevents hemorrhagic cystitis, not proximal tubular toxicity
Teaching case · illustrative composite, not a real patient
A 4-year-old girl finishing ifosfamide-based therapy for a rhabdomyosarcoma (cumulative dose approaching 90 g/m²) is noted on routine labs to have a serum phosphate of 2.1 mg/dL, bicarbonate 17 mmol/L, and 1+ glucose on urinalysis despite a normal blood glucose. Her growth has plateaued and she has started to bow at the knees.
Work-up shows a low tubular reabsorption of phosphate, a normal-anion-gap metabolic acidosis with inappropriately alkaline urine (proximal, type 2 renal tubular acidosis), glycosuria with euglycemia, generalized aminoaciduria, and elevated urinary β2-microglobulin — the full proximal-tubule (Fanconi) picture. Serum creatinine is only mildly elevated. Ifosfamide is not re-dosed; she is started on oral phosphate, alkali, and calcitriol replacement with close monitoring of growth and bone health. Over the following year the acidosis and phosphate wasting partially improve but do not fully resolve.
Teaching point — Ifosfamide injures the proximal tubule before the glomerulus: the syndrome to recognize is hypophosphatemia with phosphaturia, proximal (type 2) RTA, glycosuria with normal blood glucose, and low-molecular-weight proteinuria — in a young child on a high cumulative ifosfamide dose. It can present as hypophosphatemic rickets and growth failure, may be permanent, and mesna does not prevent it. Management is supportive electrolyte/alkali replacement and avoiding further high cumulative dosing.
How it happens
The pathophysiology as a cascade — select a step to follow the mechanism.
How we learned it
- 1987
Goren and colleagues document tubular enzymuria and proteinuria in every one of 16 patients given ifosfamide with mesna, with a time course indicating tubular cell necrosis.
Established early that mesna — which prevents hemorrhagic cystitis — does not protect the proximal tubule, so tubular toxicity is a distinct, unguarded problem.
PMID 2879626 - 1995
Ho et al. prospectively characterize acute ifosfamide nephrotoxicity in children and young adults, finding subclinical tubular changes in all patients and a 4% incidence of overt Fanconi-like syndrome, with severe β2-microglobulinuria predicting chronic damage.
Separated the near-universal acute, reversible tubular leak from the smaller subset who progress to chronic Fanconi syndrome, and named a laboratory predictor.
PMID 8625085 - 1996
Skinner et al. (Lancet) study 23 children and identify total ifosfamide dose as the only independent risk factor for chronic proximal tubular toxicity, with subnormal GFR in 45% and hypophosphatemic rickets or RTA in six.
The landmark risk-factor analysis: cumulative dose drives chronic nephrotoxicity, and doses ≥100 g/m² should be avoided in children.
PMID 8774570 - 1998
Loebstein and Koren critically review the predictive risk factors, concluding cumulative dose ≥60 g/m² is the most consistent predictor and age <5 years the strongest patient factor for severe chronic tubulopathy.
Consolidated cumulative dose and young age as the dominant, actionable risk factors a clinician can weigh at prescription.
PMID 9606250 - 2005
Benesic et al. show chloroacetaldehyde inhibits the Na+/Ca2+ exchanger in human proximal tubule cells, and Aleksa et al. demonstrate proximal tubular cells themselves metabolize ifosfamide to chloroacetaldehyde.
Localized the injury: the toxic metabolite is generated inside the proximal tubule, and disturbed calcium handling and energy failure follow.
PMID 16221203 - 2009
Oberlin et al. report ~10-year renal outcomes in 183 children: most retain normal tubular and glomerular function, but a reduced tubular phosphate threshold persists in 24% and toxicity can be permanent and progress over time.
Defined the long-term prognosis at moderate doses — mostly favorable, but with a persistent tubular signature that requires lifelong surveillance.
PMID 19826134
The landmark studies
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna
Goren MP, et al. · Cancer Treat Rep 1987 · PMID 2879626
Urinary tubular enzymes and protein rose in every patient given ifosfamide with mesna, with a time course indicating tubular cell necrosis — mesna prevents cystitis, not tubular injury.
16/16 patients with tubular enzymuria despite mesna 1.2 g/m²/day
A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults
Ho PT, et al. · Cancer 1995 · PMID 8625085
Acute subclinical tubular dysfunction occurred in all patients; 4% developed a Fanconi-like syndrome, and severe β2-microglobulinuria predicted chronic nephrotoxicity.
4% Fanconi-like syndrome; β2-microglobulin ↑70-fold (0.02→1.42 mg/mmol); aminoaciduria 21/23; phosphate threshold 1.22→0.82 mmol/L
Risk factors for ifosfamide nephrotoxicity in children
Skinner R, et al. · Lancet 1996 · PMID 8774570
Total ifosfamide dose was the only independent risk factor for chronic proximal tubular toxicity; GFR was subnormal in 45% and six children had hypophosphatemic rickets or RTA.
Median dose 100.8 g/m²; GFR low in 10/22 (45%); moderate/severe toxicity in 6/10 given >100 g/m² vs 2/10 below
Long-term evaluation of ifosfamide-related nephrotoxicity in children
Oberlin O, et al. · J Clin Oncol 2009 · PMID 19826134
At moderate cumulative doses renal toxicity was moderate overall, but a reduced tubular phosphate threshold persisted in a quarter of survivors and could be permanent and progressive.
89.5% normal tubular function; phosphate threshold reduced in 24%; glycosuria 37%; median dose 54 g/m²
What the data says now
How disproportionately each agent's FAERS reports name these phenotypes vs. all other drugs (reporting odds ratio; significant signals only, 95% CI lower bound > 1; as of 2026-07-10). A reporting signal, not incidence or proven causation.
| Agent | FANC | LYTE | ATN |
|---|---|---|---|
| Ifosfamide | Ifosfamide, Fanconi Syndrome: ROR 34.91, 170 reports | Ifosfamide, Electrolyte Disturbance: ROR 2.66, 499 reports | Ifosfamide, Acute Tubular Necrosis: ROR 2.87, 28 reports |
Overt Fanconi-like syndrome
Children/young adults on high-dose ifosfamide (prospective cohort)
PMID 8625085Subnormal GFR after ifosfamide
Children at a median ~100 g/m² cumulative dose (Skinner cohort)
PMID 8774570Persistently reduced tubular phosphate threshold
183 children at ~10-year follow-up (moderate doses)
PMID 19826134Most consistent risk factor
Critical review of pediatric predictive risk factors
PMID 9606250Strongest patient risk factor
Associated with severe, chronic proximal tubulopathy
PMID 9606250How it's managed
- 1
Recognize that mesna does not protect the tubule
Mesna neutralizes acrolein in the bladder and prevents hemorrhagic cystitis, but proximal tubular enzymuria and proteinuria occur despite adequate mesna — there is no established prophylaxis against ifosfamide tubulopathy.
Tubular toxicity in every patient despite mesna; no proven pharmacologic protection · PMID 2879626
- 2
Cap cumulative dose, especially in young children
Because total ifosfamide dose is the dominant risk factor, weigh cumulative exposure carefully: cumulative doses ≥100 g/m² should be avoided in children, and ≥60 g/m² or age <5 years should trigger heightened caution.
Dose the only independent risk factor; ≥100 g/m² to be avoided in children · PMID 8774570
- 3
Surveillance for the proximal-tubule signature
Monitor serum and urine for phosphate wasting (low tubular reabsorption of phosphate), proximal RTA, glycosuria with normal blood glucose, and low-molecular-weight proteinuria (β2-microglobulin); severe β2-microglobulinuria flags those at risk of chronic damage, and toxicity can worsen over years.
β2-microglobulinuria predicts chronic nephrotoxicity; long-term surveillance needed as toxicity can be permanent/progressive · PMID 19826134
- 4
Supportive electrolyte and alkali replacement
There is no specific antidote; management is replacing what the tubule leaks — oral phosphate, alkali for the acidosis, and (in children with rickets) calcitriol — with attention to growth and bone health.
Chronic tubular electrolyte loss requiring oral supplementation defines the clinical burden · PMID 8625085
What the guidelines say
Society and consensus recommendations addressing this syndrome, each with its key recommendation quoted verbatim.
Every citation on this page is a real, PubMed-verified reference. The teaching case is an illustrative composite, not a real patient. Medical-education content — not medical advice.